Your browser doesn't support javascript.
loading
Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study.
Biscarini, Filippo; Masetti, Giulia; Muller, Ilaria; Verhasselt, Hedda Luise; Covelli, Danila; Colucci, Giuseppe; Zhang, Lei; Draman, Mohd Shazli; Okosieme, Onyebuchi; Taylor, Pete; Daumerie, Chantal; Burlacu, Maria-Cristina; Marinò, Michele; Ezra, Daniel George; Perros, Petros; Plummer, Sue; Eckstein, Anja; Salvi, Mario; Marchesi, Julian R; Ludgate, Marian.
Afiliación
  • Biscarini F; Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, CF14 4XW, UK.
  • Masetti G; Department of Bioinformatics, Parco Tecnologico Padano Srl (PTP), Lodi, 26900, Italy.
  • Muller I; Institute of Agricultural Biology and Biotechnology, Italian National Research Council (CNR), Milan, 20133, Italy.
  • Verhasselt HL; Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, CF14 4XW, UK.
  • Covelli D; Department of Bioinformatics, Parco Tecnologico Padano Srl (PTP), Lodi, 26900, Italy.
  • Colucci G; Department of Clinical Sciences and Community Health, University of Milan, Milan, 35-I-20122, Italy.
  • Zhang L; Graves' Orbitopathy Center, Endocrinology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan, Milan, 35-I-20122, Italy.
  • Draman MS; Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, 45147, Germany.
  • Okosieme O; Cultech Ltd., Baglan, Port Talbot, SA12 7BZ, UK.
  • Taylor P; Department of Bioinformatics, Parco Tecnologico Padano Srl (PTP), Lodi, 26900, Italy.
  • Daumerie C; Graves' Orbitopathy Center, Endocrinology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan, Milan, 35-I-20122, Italy.
  • Burlacu MC; Cultech Ltd., Baglan, Port Talbot, SA12 7BZ, UK.
  • Marinò M; Graves' Orbitopathy Center, Endocrinology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan, Milan, 35-I-20122, Italy.
  • Ezra DG; Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, CF14 4XW, UK.
  • Perros P; Centre for Stem Cell Biology, School of Biosciences, University of Sheffield, Sheffield, S10 2TN, UK.
  • Plummer S; Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, CF14 4XW, UK.
  • Eckstein A; KPJ Healthcare University College, Kota Seriemas, 71800 Nilai, Negeri Sembilan, Malaysia.
  • Salvi M; Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, CF14 4XW, UK.
  • Marchesi JR; Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, CF14 4XW, UK.
  • Ludgate M; Department of Endocrinology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, B-1200, Belgium.
J Clin Endocrinol Metab ; 108(8): 2065-2077, 2023 Jul 14.
Article en En | MEDLINE | ID: mdl-36683389
ABSTRACT
CONTEXT Gut bacteria can influence host immune responses but little is known about their role in tolerance-loss mechanisms in Graves disease (GD; hyperthyroidism caused by autoantibodies, TRAb, to the thyrotropin receptor, TSHR) and its progression to Graves orbitopathy (GO).

OBJECTIVE:

This work aimed to compare the fecal microbiota in GD patients, with GO of varying severity, and healthy controls (HCs).

METHODS:

Patients were recruited from 4 European countries (105 GD patients, 41 HCs) for an observational study with cross-sectional and longitudinal components.

RESULTS:

At recruitment, when patients were hyperthyroid and TRAb positive, Actinobacteria were significantly increased and Bacteroidetes significantly decreased in GD/GO compared with HCs. The Firmicutes to Bacteroidetes (FB) ratio was significantly higher in GD/GO than in HCs. Differential abundance of 15 genera was observed in patients, being most skewed in mild GO. Bacteroides displayed positive and negative correlations with TSH and free thyroxine, respectively, and was also significantly associated with smoking in GO; smoking is a risk factor for GO but not GD. Longitudinal analyses revealed that the presence of certain bacteria (Clostridiales) at diagnosis correlated with the persistence of TRAb more than 200 days after commencing antithyroid drug treatment.

CONCLUSION:

The increased FB ratio observed in GD/GO mirrors our finding in a murine model comparing TSHR-immunized with control mice. We defined a microbiome signature and identified changes associated with autoimmunity as distinct from those due to hyperthyroidism. Persistence of TRAb is predictive of relapse; identification of these patients at diagnosis, via their microbiome, could improve management with potential to eradicate Clostridiales.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Graves / Oftalmopatía de Graves / Microbioma Gastrointestinal / Hipertiroidismo Tipo de estudio: Clinical_trials / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: J Clin Endocrinol Metab Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Graves / Oftalmopatía de Graves / Microbioma Gastrointestinal / Hipertiroidismo Tipo de estudio: Clinical_trials / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: J Clin Endocrinol Metab Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido